BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BioNexus Gene Lab Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.23+0.03 (+2.23%)
Close on Oct 19, 2026
- Market cap
- $2.97M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
BioNexus Gene Lab has not reported a dividend
No dividend per share appears in BioNexus Gene Lab's annual filings since fiscal 2017.